BIOMAT Database Logo BIOMAT Database Logo

Heparin cofactor II assay. Elimination of heparin and antithrombin-III effects. 1988

R Nakhleh, and J M Vogt, and J R Edson
Department of Laboratory Medicine and Pathology, School of Medicine, University of Minnesota, Minneapolis.

Functional assays for heparin cofactor II (HC-II) are based on the inactivation of thrombin by HC-II in the presence of dermatan sulfate (DS). Residual thrombin is measured in a chromogenic assay. Interference by the antithrombin-III (AT-III)/heparin complex, which also rapidly inactivates thrombin, must be eliminated from the HC-II test system. Commercial DS is contaminated with heparin, while plasma specimens to be tested contain AT-III. After NaNO2/acetic acid treatment of DS (to inactivate heparin), there was enough residual heparin to cause AT-III interference. Treatment of plasma with commercially available anti-AT-III antiserum largely, but not completely, removed AT-III interference from the HC-II assay. With commercially available reagents, both NaNO2/acetic acid treatment of DS and anti-AT-III treatment of plasma were needed to eliminate heparin/AT-III interference. Protamine sulfate inactivated DS as well as heparin and could not be used to reduce AT-III/heparin interference with the HC-II assay.

UI MeSH Term Description Entries
D007106 Immune Sera Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen. Antisera,Immune Serums,Sera, Immune,Serums, Immune
D008722 Methods A series of steps taken in order to conduct research. Techniques,Methodological Studies,Methodological Study,Procedures,Studies, Methodological,Study, Methodological,Method,Procedure,Technique
D009994 Osmolar Concentration The concentration of osmotically active particles in solution expressed in terms of osmoles of solute per liter of solution. Osmolality is expressed in terms of osmoles of solute per kilogram of solvent. Ionic Strength,Osmolality,Osmolarity,Concentration, Osmolar,Concentrations, Osmolar,Ionic Strengths,Osmolalities,Osmolar Concentrations,Osmolarities,Strength, Ionic,Strengths, Ionic
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006494 Heparin Antagonists Coagulant substances inhibiting the anticoagulant action of heparin. Antagonists, Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000085 Acetates Derivatives of ACETIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxymethane structure. Acetate,Acetic Acid Esters,Acetic Acids,Acids, Acetic,Esters, Acetic Acid
D000990 Antithrombin III A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily. Heparin Cofactor I,Antithrombin III-Alpha,Atenativ,Heparin Co-Factor I,Kybernin,Serpin C1,Thrombate III,Antithrombin III Alpha,Antithrombin IIIAlpha,Cofactor I, Heparin,Heparin Co Factor I
D012977 Sodium Nitrite Nitrous acid sodium salt. Used in many industrial processes, in meat curing, coloring, and preserving, and as a reagent in ANALYTICAL CHEMISTRY TECHNIQUES. It is used therapeutically as an antidote in cyanide poisoning. The compound is toxic and mutagenic and will react in vivo with secondary or tertiary amines thereby producing highly carcinogenic nitrosamines. Nitrite, Sodium
D015844 Heparin Cofactor II A sulfated plasma protein with a MW of approximately 66kDa that resembles ANTITHROMBIN III. The protein is an inhibitor of thrombin in plasma and is activated by dermatan sulfate or heparin. It is a member of the serpin superfamily. Heparin Co-Factor II,Heparin Cofactor 2,Leuserpin 2,Protease Inhibitor Leuserpin 2,Serpin D1,Heparin Co Factor II

Related Publications

R Nakhleh, and J M Vogt, and J R Edson
Antithrombin-III assay without influence of heparin cofactor II.
March 1990, Thrombosis research,
R Nakhleh, and J M Vogt, and J R Edson
[Antithrombin III and heparin cofactor II].
February 1985, Rinsho byori. The Japanese journal of clinical pathology,
R Nakhleh, and J M Vogt, and J R Edson
[Glycosaminoglycans and inhibitors (antithrombin III and heparin cofactor II)].
April 1989, Nihon rinsho. Japanese journal of clinical medicine,
R Nakhleh, and J M Vogt, and J R Edson
An improved clinical assay for antithrombin III (heparin cofactor).
August 1980, American journal of clinical pathology,
R Nakhleh, and J M Vogt, and J R Edson
Comparative studies of heparin cofactor activity toward antithrombin III and heparin cofactor II, and antithrombin III affinity between low molecular weight heparin and unfractionated heparin.
October 1990, Seminars in thrombosis and hemostasis,
R Nakhleh, and J M Vogt, and J R Edson
The progressive antithrombin (antithrombin-III, heparin-cofactor).
January 1974, Haematologia,
R Nakhleh, and J M Vogt, and J R Edson
Assessment of interference by heparin cofactor II in the DuPont aca antithrombin-III assay.
April 1988, American journal of clinical pathology,
R Nakhleh, and J M Vogt, and J R Edson
Increased concentrations of heparin cofactor II in diabetic patients, and possible effects on thrombin inhibition assay of antithrombin III.
January 1989, Clinical chemistry,
R Nakhleh, and J M Vogt, and J R Edson
Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo.
March 1995, Thrombosis and haemostasis,
R Nakhleh, and J M Vogt, and J R Edson
Heparin cofactor II deficiency in the elderly: comparison with antithrombin III.
June 1992, Thrombosis research,
Copied contents to your clipboard!